Kodiak Sciences Inc. (KOD)

Market Cap	461.69M
Revenue (ttm)	n/a
Net Income (ttm)	-199.83M
Shares Out	52.70M
EPS (ttm)	-3.79
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	23,485
Open	8.64
Previous Close	8.55
Day's Range	8.55 - 8.87
52-Week Range	1.92 - 11.60
Beta	2.45
Analysts	Hold
Price Target	11.75 (+34.13%)
Earnings Date	Aug 13, 2025

About KOD

Kodiak Sciences Inc., a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor (VEGF) antibody biopolymer that has complete Phase 3 clinical study to treat high prevalence retinal vascular diseases; and in Phase 3 clinical study for the treatment of diabetic retinopathy, wet age-related macular degeneration (AMD), retinal vein occlusion, and diabetic mac...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Oct 4, 2018
• Employees: 109
• Stock Exchange: NASDAQ
• Ticker Symbol: KOD
• Website: https://kodiak.com

Analyst Summary

According to 4 analysts, the average rating for KOD stock is "Hold." The 12-month stock price target is $11.75, which is an increase of 34.13% from the latest price.

Price Target

$11.75

(34.13% upside)

Analyst Consensus: Hold